彌漫性大B細(xì)胞淋巴瘤是亞洲人最常見的淋巴腫瘤亞型，經(jīng)過R-CHOP方案治療后仍有相當(dāng)一部分患者表現(xiàn)為難治或復(fù)發(fā)。彌漫性大B細(xì)胞淋巴瘤的常見致病信號(hào)通路有B細(xì)胞受體、Toll樣受體4/髓樣分子因子88/核因子-κB、磷脂酰肌醇3-激酶/蛋白激酶B信號(hào)通路，靶向藥物包括Bruton酪氨酸激酶抑制劑、來那度胺、硼替佐米、凋亡蛋白抑制劑抑制劑、磷脂酰肌醇3-激酶抑制劑、蛋白激酶B抑制劑、哺乳動(dòng)物雷帕霉素靶蛋白抑制劑。闡述了彌漫性大B細(xì)胞淋巴瘤中常見致病信號(hào)通路及其遺傳學(xué)改變，并總結(jié)了相關(guān)通路常見的靶向藥物的研究進(jìn)展。

Diffuse large B cell lymphoma is the most common subtype of lymphoma in Asians. A significant proportion of patients remain refractory or relapsed after R-CHOP regimen. The common pathogenic signaling pathways of diffuse large B-cell lymphoma include B cell receptor (BCR), TLR-MYD88-NF-κB, and PI3K/Akt signaling pathway. Targeted drugs include BTK inhibitors, lenalidomide, bortezomib, IAP inhibitors, PI3K inhibitors, Akt inhibitors, and mTOR inhibitor. This article describes the common pathogenic signaling pathways and their genetic changes in diffuse large B-cell lymphoma, and summarizes the research progress on drugs targeted related pathways.

R979.1

貴州省科技計(jì)劃項(xiàng)目(黔科合支撐[2019]2788號(hào))